Kimberly-Clark (KMB) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Launched the multi-year Powering Care transformation strategy and reorganized into three segments, driving innovation, volume gains, and efficiencies for reinvestment and shareholder returns.
Full-year 2024 results exceeded long-term growth targets, establishing a strong foundation for accelerated strategy and value creation in 2025.
Focused on pioneering innovation, margin optimization, and organizational rewiring to drive value creation.
Entering 2025 with high confidence in innovation-led growth and continued investment in product quality, brand support, and productivity initiatives.
Financial highlights
FY24 organic sales grew 3.2% year-over-year; Q4 organic sales up 2.3% with 1.5% volume growth and 0.6% price increase.
Adjusted operating profit grew 15.6% year-over-year on a constant-currency basis; Q4 adjusted operating profit was $684M, up 2.1%.
Adjusted EPS increased 17.7% year-over-year on a constant-currency basis; FY adjusted EPS was $7.30, up 11.1%.
Adjusted gross margin improved by 2 percentage points to 36.5% in FY24; Q4 adjusted gross margin was 35.4%, up 50 bps.
Productivity savings reached a historical high of 5.9% in 2024, with a target of 5% for 2025.
Outlook and guidance
2025 organic sales growth expected to outpace category averages (~2%), led by volume and mix, with reported net sales facing a ~300 bps currency headwind and ~240 bps impact from divestitures and business exits.
Adjusted operating profit and EPS projected to grow at high and mid-to-high single-digit rates, respectively, on a constant-currency basis, but with significant negative impacts from currency and divestitures.
Revenue and profit expected to be evenly distributed between first and second half of 2025.
Gross margin expansion to continue in 2025, but at a slower pace; operating margin expected to grow faster than gross margin due to SG&A savings.
Adjusted free cash flow guidance of $2B+ for 2025, with $1.0–$1.2B in capital expenditures.
Latest events from Kimberly-Clark
- Adjusted EPS up 10.4% in Q2 2026, but China disruption tempers full-year outlook.KMB
Q2 2026 Prepared Remarks - Adjusted EPS rose 10.4% in Q2 2026, but China disruption led to a cautious outlook.KMB
Q2 2026 (Q&A) - Kenvue integration and innovation drive growth, productivity, and strong shareholder returns.KMB
23rd annual dbAccess Global Consumer Conference - Strong growth, strategic acquisitions, and board elections defined the meeting's outcomes.KMB
AGM 2026 - Transforming through innovation and acquisitions to build a global health and wellness leader.KMB
Barclays 18th Annual Americas Select Conference - Acquisition targets $1.9B in synergies, leveraging complementary strengths for growth.KMB
Morgan Stanley Global Consumer & Retail Conference 2025 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2029.KMB
M&A Announcement - Q3 2024 delivered higher adjusted EPS and profit, reaffirming a strong 2024 outlook.KMB
Q3 2024 - Premiumization, innovation, and efficiency drive double-digit shareholder returns and growth.KMB
Deutsche Bank dbAccess 2024 Global Consumer Conference